期刊文献+

包裹性腹膜硬化症的发病机制及防治 被引量:6

Pathogenesis and management of encapsulating peritoneal sclerosis in peritoneal dialysis
下载PDF
导出
摘要 包裹性腹膜硬化症(EPS)是由于腹膜广泛增厚黏连导致持续或反复出现肠梗阻的一组临床综合征。EPS是长期腹膜透析(PD)患者中一种少见但严重的并发症。腹膜炎症、新生血管形成及纤维化是形成EPS的关键步骤,腹膜纤维化和黏连是EPS的核心。目前EPS的发病机制尚未完全明确,仍然缺乏理想的治疗手段。本文将对EPS发病机制及防治研究进展做一综述。 Encapsulating peritoneal sclerosis ( EPS) has been defined as a clinical syndrome continuously, intermittently, or repeatedly presenting with symptoms of intestinal obstruction due to adhesions of a diffusely thickened peritoneum. EPS is a serious complication that can occur during long-term peritoneal dialysis ( PD) , although only a small percentage of PD patients develop EPS. Inflammation, angiogenesis, and fibrosis of the peritoneum are the key factors while peritoneal fibrosis and adhesion is the core element. The precise mechanism underlying EPS remains unclear and the optimal management regime for EPS is yet to be established. New research progresses on pathogenesis and preventive/therapeutic strategies of EPS will be presented in this review.
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2015年第6期573-577,共5页 Chinese Journal of Nephrology,Dialysis & Transplantation
关键词 包裹性腹膜硬化症 腹膜纤维化 腹膜透析 encapsulating peritoneal sclerosis peritoneal fibrosis peritoneal dialysis
  • 相关文献

参考文献25

  • 1Gandhi VC, Humayun HM, Ing TS, et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med, 1980,140(9) : 1201-1203.
  • 2Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan : A prospective, controlled, muhicenter study. Am J Kidney Dis, 2004,44 (4) : 729-737.
  • 3Stefanidis C J, Shroff R. Encapsulating peritoneal sclerosis in children. Pediatric Nephrology,2014,29(11) :2093-2103.
  • 4Nakayama M, Miyazaki M, Honda K, et al. Encapsulating Peritoneal Sclerosis in the Era of a Multi-Disciplinary Approach Based on Biocompatible Solutions: the NEXT-PD Study.Perit Dial Int,2014,3d (7) : 766-774.
  • 5Shroff R, Stefanidis CJ, Askiti V, et al. Encapsulating peritoneal sclerosis in children on chronic PD: a survey from the European Paediatric Dialysis Working Group.Nephrol Dial Transplant, 2013,28 (7) : 1908-1914.
  • 6Johnson DW, Cho Y, Livingston BE, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int, 2010, 77 (I0) :904-912.
  • 7Korte MR, Sampimon DE, Lingsma HF, et al. Risk factors associated with encapsulating peritoneal sclerosis in dutch eps study. Petit Dial Int, 2011,31 (3) : 269-278.
  • 8Yung S, Lui SL, Ng CK, et al. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers. Petit Dial Int,2015,35(2) :147-158.
  • 9Kawanishi K, Honda K, Tsukada M, et al. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis. Petit Dial Int,2013,33(3) :242-251.
  • 10Working Group Committee for Preparation of Guidelines for Peritoneal Dialysis,Japanese Society for Dialysis Therapy; Japanese Society for Dialysis Therapy. 2009 Japanese Society for Dialysis Therapy guidelines for peritoneal dialysis. Ther Apher Dial, 2010, 14 ( 6 ) : 489-504.

同被引文献34

引证文献6

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部